1350 ET -- German drug developer Evotec is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Halozyme Therapeutics said it was ending an effort to acquire Evotec. Halozyme Chief Executive Helen Torley said Friday that Evotec has been unwilling to engage on a potential deal, leading the biopharmaceutical company to withdraw its proposal. San Diego-based Halozyme last week made a non-binding proposal to acquire Evotec for 11 euros a share in cash that put the deal's valuation around 2 billion euros ($2.09 billion). Dow Jones & Co. owns Factiva. (matthew.walker@dowjones.com)
(END) Dow Jones Newswires
November 22, 2024 13:50 ET (18:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Comments